Capricor Therapeutics Inc (OTCMKTS:CAPR) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Tuesday.

According to Zacks, “Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California. “

Separately, Roth Capital set a $12.00 target price on Capricor Therapeutics and gave the company a “buy” rating in a research note on Thursday, October 20th.

Shares of Capricor Therapeutics (OTCMKTS:CAPR) opened at 2.95 on Tuesday. Capricor Therapeutics has a one year low of $1.88 and a one year high of $5.40. The company’s market capitalization is $52.96 million. The stock has a 50 day moving average price of $3.15 and a 200-day moving average price of $3.58.

Capricor Therapeutics (OTCMKTS:CAPR) last issued its quarterly earnings data on Monday, August 15th. The company reported ($0.26) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.24) by $0.02. Equities research analysts predict that Capricor Therapeutics will post ($1.04) earnings per share for the current fiscal year.

In other Capricor Therapeutics news, major shareholder Sinai Medical Center Cedars purchased 312,500 shares of the company’s stock in a transaction that occurred on Wednesday, September 21st. The stock was purchased at an average cost of $3.20 per share, with a total value of $1,000,000.00. Following the acquisition, the insider now directly owns 2,904,798 shares of the company’s stock, valued at approximately $9,295,353.60. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.

Large investors have recently added to or reduced their stakes in the stock. LLBH Private Wealth Management LLC boosted its stake in Capricor Therapeutics by 4.2% in the third quarter. LLBH Private Wealth Management LLC now owns 124,591 shares of the company’s stock worth $404,000 after buying an additional 5,000 shares in the last quarter. Granite Point Capital Management L.P. acquired a new stake in Capricor Therapeutics during the third quarter worth $219,000. Finally, Vanguard Group Inc. boosted its stake in Capricor Therapeutics by 25.6% in the second quarter. Vanguard Group Inc. now owns 27,975 shares of the company’s stock worth $111,000 after buying an additional 5,704 shares in the last quarter.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications.

Receive News & Stock Ratings for Capricor Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics Inc and related stocks with our FREE daily email newsletter.